Hypertension Diagnostics Announces FY 2007 First Quarter Results

ST. PAUL, MN November 14, 2006 – Hypertension Diagnostics, Inc. (OTC: HDII.OB), today announced financial results for the first quarter of fiscal year 2007 ended September 30, 2006. Revenue for the quarter totaled $422,485 compared to $380,916 in the prior year’s first quarter ended September 30, 2005, which represents an 11% increase. The Company incurred a net loss of $188,081 for the quarter or $0.00 per share compared with a net loss of $337,217 for the prior year’s quarter or $(.01) per share. Included in the net loss of $188,081 for the quarter are total non-cash charges (expenses associated mainly with stock compensation, depreciation, stock options) of $87,206. Included in the net loss of $337,217 for the prior year’s quarter were non-cash charges of $43,256. The Company reported a cash balance of $1,565,138 on September 30, 2006. Total tests transmitted, a key metric for gauging customer usage, was 7,632 for the quarter, a 14% increase from the prior year’s quarterly transmissions.
 

 

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 2006 Annual Report on Form 10-KSB, and subsequent Quarterly Reports on 10-QSB, all of which were filed with the U.S. Securities and Exchange Commission, as well as others not now anticipated.

View PDF file: Q1 2007 Results
 

CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.

Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Website: www.HDII.com


Contact: Mark Schwartz, CEO
651-687-9999

Return to the Main HDI Newsroom

   

Back to Top

 

 

     

Copyright © 2010 Hypertension Diagnostics, Inc
Last revised Wednesday June 23, 2010
HDI Legal Information